The continuous glucose monitoring pricing dilemma for Type 2 diabetes

May 14, 2021 | Case Study

Kaiser Health News recently published an article calling into question the efficacy of minimally invasive continuous glucose monitoring (CGM) solutions for non-insulin-treated Type 2 diabetic patients. These CGM solutions are inserted under the skin and typically measure interstitial glucose levels, much like their traditional pricking method counterparts. However, for this diabetic population, measuring hemoglobin A1c (HbA1c) better monitors the disease. The article references a 2017 study that found no indication of lowering HbA1c after one year of individuals self-monitoring glucose levels. Without insurance in the U.S, the annual cost of CGM systems can reach more than $6,000.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978